Most pituitary tumors are non-invasive, benign adenomas that remain confined to the sella turcica. Although there is, at present, no accepted definition of aggressive pituitary adenomas, one would suggest that these have a tendency to recur after initial surgery. They have a rapid growth rate and invade surrounding structures such as the sphenoid and cavernous sinus as well as the skull base bone. They are clinically difficult to manage and present major problems due to incomplete resection. To date, 20 cases have been treated. 8, 9, 16, 19, 20, [24] [25] [26] 28 The time between disease presentation and temozolomide administration varied between five and 23 years (mean time 10.7). The group included eight PRL-secreting, eight ACTH-secreting, three clinically non-functional, and one silent corticotroph carcinomas. Fourteen of the 20 patients (70 %) showed a clinical and radiologic response to temozolomide.
The standard therapeutic dose of temozolomide is 150-200 mg/m 2 on Days 1-5 of an 28-day cycle (5/28). Depletion of MGMT has been proposed as a means of tumor response to temozolomide. 44 Experimental and clinical data have shown that response to temozolomide is schedule-dependent and that alternative dosing regimens may enhance the drug's efficacy. 45, 46 The antiangiogenic effect of the drug is optimized by administering low doses on a frequent or continuous schedule without extended interruptions ('metronomic' chemotherapy), thus achieving MGMT depletion and improving response.
Thus the recommended dose is 50 mg/m 2 /day without interruption over a 28-day cyle (28/28). Temozolomide absorption is minimally affected by food. Furthermore, no serious side effects have been reported when using temozolomide to treat patients with pituitary tumors. Common, non-hematologic adverse effects include nausea, vomiting, fatigue, headache, and constipation, most of which are mild-to-moderate.
As previously stated, MGMT is a DNA repair protein reversing the effect of temozolomide 47 by removing alkylating adducts, counteracting its effect, 48 and conferring resistance. 49 Low-level expression in a wide spectrum of human tumors is thought to result from epigenetic silencing, by hypermethylation of the MGMT gene promoter. 49, 50 Low-level MGMT immunoexpression is considered a predictive and prognostic marker in patients with temozolomide-treated glioblastomas. 51 This observation has been extended to aggressive adenohypophysial tumors and carcinomas.
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Pituitary Carcinomas Treated with Temozolomide
Pituitary carcinomas are difficult to manage despite the use of various therapies, including repeated surgeries, radiation, and drugs. To date, 20 cases have been treated. 8, 9, 16, 19, 20, [24] [25] [26] 28 The time between disease presentation and temozolomide administration varied between five and 23 years (mean time 10.7). The group included eight PRL-secreting, eight ACTH-secreting, three clinically non-functional, and one silent corticotroph carcinomas. Fourteen of the 20 patients (70 %) showed a clinical and radiologic response to temozolomide.
Aggressive Pituitary Adenomas Treated with Temozolomide
After the successful treatment reports in pituitary carcinomas, the first case of a pituitary adenoma treated with temozolomide was reported in 2006. 10 
Response to Treatment and Indications
In three out of 52 cases, morphologic comparison was possible. These tumors had been investigated before and after temozolomide treatment. Two tumors responded to treatment temozolomide and showed hemorrhage, necrosis, focal fibrosis, inflammatory infiltration, fewer mitoses, and a lower Ki-67 nuclear labeling index. 11, 26 The third tumor showed no changes. 13 In patients responding to temozolomide, the clinical response was rapid and associated with a fast decrease in tumor volume. In patients with PRL-and ACTH-secreting tumors, an almost immediate reduction of plasma hormone levels was seen after the commencement of therapy, allowing the rapid evaluation of treatment response. Three basic patterns of radiographic changes were described on magnetic resonance imaging: tumor necrosis and hemorrhage, 10,11 cystic change, 22 and shrinkage. Demonstration of MGMT immunoreactivity appears to be useful in identifying non-responders to temozolomide treatment. However, some studies concluded that MGMT immunoexpression is not reliable and does not properly predict success of temozolomide therapy. Therefore, due to these contradictory results and also to the lack of other available medications, temozolomide therapy may be introduced independently of MGMT status. 6, 25 Based on the published cases and the reported response rates, temozolomide therapy could be used in:
• aggressive PRL-secreting pituitary tumors resistant to bromocriptine or cabergoline that continue to grow after surgery and radiotherapy; 
